The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 23, 2013
Filed:
Mar. 23, 2010
Umesh B. Gangadharmath, Los Angeles, CA (US);
Hartmuth C. Kolb, Playa Del Rey, CA (US);
Peter J. H. Scott, Ypsilanti, MI (US);
Joseph C. Walsh, Pacific Palisades, CA (US);
Wei Zhang, Los Angeles, CA (US);
Anna Katrin Szardenings, Torrance, CA (US);
Anjana Sinha, San Diego, CA (US);
Gang Chen, Los Angeles, CA (US);
Eric Wang, San Diego, CA (US);
Vani P. Mocharia, Los Angeles, CA (US);
Chul Yu, Los Angeles, CA (US);
Changhui Liu, Los Angeles, CA (US);
Daniel Kurt Cashion, Manhattan Beach, CA (US);
Dhanalakshmi Kasi, Los Angeles, CA (US);
Umesh B. Gangadharmath, Los Angeles, CA (US);
Hartmuth C. Kolb, Playa Del Rey, CA (US);
Peter J. H. Scott, Ypsilanti, MI (US);
Joseph C. Walsh, Pacific Palisades, CA (US);
Wei Zhang, Los Angeles, CA (US);
Anna Katrin Szardenings, Torrance, CA (US);
Anjana Sinha, San Diego, CA (US);
Gang Chen, Los Angeles, CA (US);
Eric Wang, San Diego, CA (US);
Vani P. Mocharia, Los Angeles, CA (US);
Chul Yu, Los Angeles, CA (US);
Changhui Liu, Los Angeles, CA (US);
Daniel Kurt Cashion, Manhattan Beach, CA (US);
Dhanalakshmi Kasi, Los Angeles, CA (US);
Eli Lilly and Company, Indianapolis, IN (US);
Abstract
Imaging agents of formula (I) and methods for detecting neurological disorders comprising administering ti a patient in need compounds of formula (I) capable of binding to tau proteins and β-amyloid peptides are presented herein. The invention also relates to methods of imaging Aβ and tau aggregates comprising introducing a detectable quantity of pharmaceutical formulation comprising a radiolabeled compound of formula (I) and detecting the labeled compound associated with amyloid deposits and/or tau proteins in a patient. These methods and compositions enable preclinical diagnosis and monitoring progression of AD and other neurological disorders.